Regenerative Therapy for Cardiomyopathies

Wang, Zi; Su, Xuan; Ashraf, Muhammad; Kim, Il-man; Weintraub, Neal L.; Jiang, Meng; Tang, Yaoliang

doi:10.1007/s12265-018-9807-z

Cited by 21 publications

(19 citation statements)

References 100 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the revascularization treatments, such as percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) surgery, can reopen occluded coronary arteries in patients with coronary artery disease[6], current research shows that these treatments are inefficient in solving microvascular dysfunction (CMD)[7], so the risk myocardium is still in a microenvironment with insufficient blood supply, which trig cell apoptosis[8]. The progressive apoptosis of cardiomyocytes exacerbates adverse left ventricular remodeling and ultimately promotes the progress of chronic heart failure[5]. …”

Section: Introductionmentioning

confidence: 99%

“…Ischemic heart disease is the leading cause of death in the developed and developing countries[1]. An acute myocardial infarction can lead to rapid loss of billions of adult cardiomyocytes[2], however, adult hearts have very limited capacity for regeneration[3], therefore, replacement of dead cardiomyocytes with scar tissue leads to left ventricular remodeling and heart failure[4, 5]. While the revascularization treatments, such as percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) surgery, can reopen occluded coronary arteries in patients with coronary artery disease[6], current research shows that these treatments are inefficient in solving microvascular dysfunction (CMD)[7], so the risk myocardium is still in a microenvironment with insufficient blood supply, which trig cell apoptosis[8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes for Angiogenesis

Shen

et al. 2018

J. of Cardiovasc. Trans. Res.

Self Cite

View full text Add to dashboard Cite

We demonstrated the effects of exosomes secreted by cardiac mesenchymal stem cells (C-MSC-Exo) in protecting acute ischemic myocardium from reperfusion injury. To investigate the effect of exosomes from C-MSC on angiogenesis. We injected C-MSC-Exo or PBS intramuscularly into ischemic hind limb. Blood perfusion of limb was evaluated by laser Doppler Imaging. We observed that ischemic limb treated with C-MSC-Exo exhibit improved blood perfusion compared to ischemic limb treated with PBS at 2 weeks and 1 month after induction of limb ischemia. To explore the potential mechanisms underlying C-MSC-Exo’s angiogenetic effect, we performed microRNA array analysis, and identify mmu-miR-7116-5p as the most abundant enriched miRNA detected in C-MSC-Exo. Bioinformatics’ analysis shows that miR-7116-5p negatively regulates of protein polyubiquitination. In conclusion, our study demonstrated that intramuscular delivery of C-MSC-Exo after limb ischemia improves blood perfusion, and we identified most abundant miRNAs that are preferentially enriched in C-MSC-Exo.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes for Angiogenesis

Shen

et al. 2018

J. of Cardiovasc. Trans. Res.

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, post transplantation almost 85 percent of donor stem cells are lost within the first 24 h; [130] mitigating factors such as patient characteristics, e.g. sex, age, underlying medical conditions, etc., immune rejection of transplanted cells, obstruction of the micro-vasculature and tumor formation also merit consideration [131] [132]. Benefits of regenerative cell treatments may depend on myocardial location; success of stem cell or cardiomyocyte applications to the epicardial surface of the heart, which differ from intra-myocardial injections for a host of reasons amongst species.…”

Section: Limitationsmentioning

confidence: 99%

Myocardial Infarction: Perspectives on Cardiac Regeneration and Cardiac Remote Conditioning Interventions to Limit Cellular Injury

Kingma¹

2020

WJCD

View full text Add to dashboard Cite

Acute myocardial infarction initiates a cascade of events including loss of protein homeostasis and chronic inflammation that affect overall cellular repair and senescence. This contributes to loss of cardiomyocytes and consequent formation of fibrotic scar. In certain vertebrate species, the heart can completely self-repair or regenerate after myocardial injury; however, this does not appear to be the case for humans. Despite this limitation, studies using novel non-pharmacologic interventions designed to protect against ischemic damage and to improve patient outcomes are ongoing. Remote ischemic conditioning stratagems are used to attenuate ischemia-reperfusion injury in clinical and animal studies; endogenous protective factors that stimulate complex signal transduction pathways are deemed responsible. Some of these factors could conceivably act in concert with those involved in regulating cardiovascular regeneration. Numerous studies have focused on cardiac regenerative interventions using stem-cell based therapies and transplantation of cardiomyocyte (or other cell types) or biocompatible matrices. This review discusses recent progress of pre-clinical and clinical translational studies for cardiac regeneration. In addition, we submit that interventions using cellular adjunctive therapies combined with remote ischemic conditioning may prove to be of interest in the battle to find novel strategies for protection against cardiac injury. are described in the scientific literature; myocardial stunning, i.e. viable cardiomyocytes that exhibit prolonged post-ischemic contractile dysfunction even after reperfusion, and myocardial hibernation, i.e. viable, but chronically contractile dysfunctional cardiomyocytes. While the pathogenesis of cell death in non-cardiac cells is less considered in most studies, it is clear that vascular endothelial and smooth muscle cells along with nervous system components within the ischemic zone are negatively affected by coronary occlusion; this contributes significantly to overall loss of cardiac contractile function and limits recovery potential. Loss of these myocardial components probably renders the affected tissue non-salvageable for a number of reasons including no-reflow, or disrupted electrical conduction, etc. Timely reperfusion of the infarct-related artery by various clinical strategies (just enumerate them as reperfusion therapy which may be pharmacological, primary percutaneous coronary intervention, primary PCI, urgent coronary artery bypass graft, appears to limit overall myocardial damage; however, reperfusion itself may exacerbate injury via apoptosis or autophagy [19]. While patient survival after ischemia has markedly improved over the last forty years, the prevalence of chronic heart failure due, in part, to remodeling of the damaged left ventricle has also increased [20] [21]. Cardiac repair is a complex, tightly regulated process between innate and immune systems [22] that includes inflammation and infiltration of the infarct area by immune cell subtypes (neutro...

show abstract

“…Combining different types of stem cells lead to superior outcome in eliciting cardiac repair. Emerging approaches, including genetic modification, stem cell-derived exosomes, and new pharmacological drugs, have been applied to improve the efficacy of stem cell therapy [62]. It will be important to investigate the mechanisms that induce the myogenic effects of GDF11 with therapeutic possibilities for a variety of age-related diseases in association with cell therapy.…”

Section: Limits and Criticism Concerning The Properties Of Gdf11: mentioning

confidence: 99%

Regenerative Capacity of Endogenous Factor: Growth Differentiation Factor 11; a New Approach of the Management of Age-Related Cardiovascular Events

Rochette

Méloux

Rigal

et al. 2018

IJMS

View full text Add to dashboard Cite

Aging is a complicated pathophysiological process accompanied by a wide array of biological adaptations. The physiological deterioration correlates with the reduced regenerative capacity of tissues. The rejuvenation of tissue regeneration in aging organisms has also been observed after heterochronic parabiosis. With this model, it has been shown that exposure to young blood can rejuvenate the regenerative capacity of peripheral tissues and brain in aged animals. An endogenous compound called growth differentiation factor 11 (GDF11) is a circulating negative regulator of cardiac hypertrophy, suggesting that raising GDF11 levels could potentially treat or prevent cardiac diseases. The protein GDF11 is found in humans as well as animals. The existence of endogenous regulators of regenerative capacity, such as GDF11, in peripheral tissues and brain has now been demonstrated. It will be important to investigate the mechanisms with therapeutic promise that induce the regenerative effects of GDF11 for a variety of age-related diseases.

show abstract

Regenerative Therapy for Cardiomyopathies

Cited by 21 publications

References 100 publications

Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes for Angiogenesis

Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes for Angiogenesis

Myocardial Infarction: Perspectives on Cardiac Regeneration and Cardiac Remote Conditioning Interventions to Limit Cellular Injury

Regenerative Capacity of Endogenous Factor: Growth Differentiation Factor 11; a New Approach of the Management of Age-Related Cardiovascular Events

Contact Info

Product

Resources

About